New Immunotherapeutic Approaches for Glioblastoma
Glioblastoma (GBM) is the most common primary malignant brain tumor with a high mortality rate. The current treatment consists of surgical resection, radiation, and chemotherapy; however, the median survival rate is only 12–18 months despite these alternatives, highlighting the urgent need to find n...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2021/3412906 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556876921831424 |
|---|---|
| author | Gustavo Ignacio Vázquez Cervantes Dinora F. González Esquivel Saúl Gómez-Manzo Benjamín Pineda Verónica Pérez de la Cruz |
| author_facet | Gustavo Ignacio Vázquez Cervantes Dinora F. González Esquivel Saúl Gómez-Manzo Benjamín Pineda Verónica Pérez de la Cruz |
| author_sort | Gustavo Ignacio Vázquez Cervantes |
| collection | DOAJ |
| description | Glioblastoma (GBM) is the most common primary malignant brain tumor with a high mortality rate. The current treatment consists of surgical resection, radiation, and chemotherapy; however, the median survival rate is only 12–18 months despite these alternatives, highlighting the urgent need to find new strategies. The heterogeneity of GBM makes this tumor difficult to treat, and the immunotherapies result in an attractive approach to modulate the antitumoral immune responses favoring the tumor eradication. The immunotherapies for GMB including monoclonal antibodies, checkpoint inhibitors, vaccines, and oncolytic viruses, among others, have shown favorable results alone or as a multimodal treatment. In this review, we summarize and discuss promising immunotherapies for GBM currently under preclinical investigation as well as in clinical trials. |
| format | Article |
| id | doaj-art-3ca1a9562e32448bbba54ca3c7217e13 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-3ca1a9562e32448bbba54ca3c7217e132025-02-03T05:44:08ZengWileyJournal of Immunology Research2314-88612314-71562021-01-01202110.1155/2021/34129063412906New Immunotherapeutic Approaches for GlioblastomaGustavo Ignacio Vázquez Cervantes0Dinora F. González Esquivel1Saúl Gómez-Manzo2Benjamín Pineda3Verónica Pérez de la Cruz4Neurochemistry and Behavior Laboratory, National Institute of Neurology and Neurosurgery “Manuel Velasco Suárez”, Mexico City 14269, MexicoNeurochemistry and Behavior Laboratory, National Institute of Neurology and Neurosurgery “Manuel Velasco Suárez”, Mexico City 14269, MexicoLaboratorio de Bioquímica Genética, Instituto Nacional de Pediatría, Secretaría de Salud, México City 04530, MexicoNeuroimmunology Department, National Institute of Neurology and Neurosurgery “Manuel Velasco Suárez”, Mexico City 14269, MexicoNeurochemistry and Behavior Laboratory, National Institute of Neurology and Neurosurgery “Manuel Velasco Suárez”, Mexico City 14269, MexicoGlioblastoma (GBM) is the most common primary malignant brain tumor with a high mortality rate. The current treatment consists of surgical resection, radiation, and chemotherapy; however, the median survival rate is only 12–18 months despite these alternatives, highlighting the urgent need to find new strategies. The heterogeneity of GBM makes this tumor difficult to treat, and the immunotherapies result in an attractive approach to modulate the antitumoral immune responses favoring the tumor eradication. The immunotherapies for GMB including monoclonal antibodies, checkpoint inhibitors, vaccines, and oncolytic viruses, among others, have shown favorable results alone or as a multimodal treatment. In this review, we summarize and discuss promising immunotherapies for GBM currently under preclinical investigation as well as in clinical trials.http://dx.doi.org/10.1155/2021/3412906 |
| spellingShingle | Gustavo Ignacio Vázquez Cervantes Dinora F. González Esquivel Saúl Gómez-Manzo Benjamín Pineda Verónica Pérez de la Cruz New Immunotherapeutic Approaches for Glioblastoma Journal of Immunology Research |
| title | New Immunotherapeutic Approaches for Glioblastoma |
| title_full | New Immunotherapeutic Approaches for Glioblastoma |
| title_fullStr | New Immunotherapeutic Approaches for Glioblastoma |
| title_full_unstemmed | New Immunotherapeutic Approaches for Glioblastoma |
| title_short | New Immunotherapeutic Approaches for Glioblastoma |
| title_sort | new immunotherapeutic approaches for glioblastoma |
| url | http://dx.doi.org/10.1155/2021/3412906 |
| work_keys_str_mv | AT gustavoignaciovazquezcervantes newimmunotherapeuticapproachesforglioblastoma AT dinorafgonzalezesquivel newimmunotherapeuticapproachesforglioblastoma AT saulgomezmanzo newimmunotherapeuticapproachesforglioblastoma AT benjaminpineda newimmunotherapeuticapproachesforglioblastoma AT veronicaperezdelacruz newimmunotherapeuticapproachesforglioblastoma |